Chronic myeloid leukaemia (CML) is associated with the BCR-ABL oncogene with 750 patients diagnosed yearly in the UK. Treatment with Imatinib Mesylate (IM), which inhibits the activity of BCR-ABL, has been clinically successful yet ~20% of patients develop drug resistance with imminent death occurring within 12-months.
Given the genetic plasticity of innate immune cells, as well as the clinical observations of drug resistance, it is tempting to speculate that leukaemic myeloid cells can be reprogrammed to become BCR-ABL independent. Definitive proof of such oncogenic programming of the myeloid genome has been lacking.
We established drug resistant clones from the KCL22 cell model; each recapitulating the clinical observations with BCR-ABL activity abolished by IM yet the cells continue to survive. Oncogene-memory was determined by siRNA knockdown approaches whereby targeting of BCR-ABL protein in parental cells induced immediate cell death while drug resistant derivatives continue to grow and survive.
Objectives:
Molecular characterise the newly reprogrammed gene network that establishes oncogene-memory
Target specific biological pathways of the defined oncogene-memory (cell cycle, metabolism) in attempts to induce apoptosis thus laying the foundation for future generations of novel therapies.
The project will employ a systems-biology approach (genome wide expression analysis, bio-informatics and shRNA technology) with the specific aims to (i) identify regulatory factors whose expression is dysregulated as a direct consequence of BCR-ABL activity and (ii) attempt to rescue the developmental block by restoring the functional activity of these dysregulated genes.
